Goldman Sachs resumes coverage on Watson Pharmaceuticals (NYSE: WPI) with a Conviction Buy list rating and $85 price target.

This article: 124 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE